Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Skylark Bio has received a unanimous recommendation from an independent Data Safety Monitoring Board (DSMB) to advance its investigational gene therapy, SKY-GJB2, into the next age group in the SONIX Phase 1/2 clinical trial for children with GJB2-related hearing loss.

The recommendation follows a review of safety data from the first four children, aged 2 to 7 years, who received the treatment in the initial trial group. Based on the available safety findings, the DSMB has supported moving the study forward to the second group, which will include younger children aged 9 months to less than 2 years.

The SONIX study is the first clinical trial to evaluate a gene therapy specifically designed to treat GJB2-related hearing loss. This condition is the most common genetic cause of inherited hearing loss in children.

SKY-GJB2 is a potential one-time gene therapy designed to address the genetic cause of hearing loss. It works by delivering a functional copy of the GJB2 gene to supporting cells in the inner ear. The goal is to restore the function of connexin 26, a protein that plays an important role in maintaining normal hearing.

Currently, there are no approved treatments that directly address the underlying genetic cause of GJB2-related hearing loss. Hearing aids and cochlear implants can help children access sound, but they do not correct the genetic problem.

The SONIX Phase 1/2 trial is a multicenter, open-label study involving children aged 9 months to 7 years. Researchers are evaluating the safety and tolerability of SKY-GJB2, along with early signs of improvement in hearing function. The treatment is given as a single injection into one ear using an investigational delivery device.

Skylark Bio said the study remains on track to generate preliminary clinical data by the end of 2026, with initial clinical results expected to be presented in 2027.

Jodi Cook, Ph.D., Chief Executive Officer of Skylark Bio, said the DSMB recommendation marks an important milestone for the SKY-GJB2 program. She highlighted the importance of advancing treatment into younger children during a key period of hearing and language development.

The company is also developing other genetic medicine programs, including SKY-AS for Angelman syndrome and SKY-PEN for SLC26A4-related hearing loss.

The latest progress marks an important step in the development of gene therapies for inherited hearing disorders. If successful, SKY-GJB2 could offer a new treatment approach for children with GJB2-related hearing loss by targeting the genetic cause rather than managing only its symptoms.

You might also like